Research progress of statins on immune regulation of multiple sclerosis and experimental allergic encephalomyelitis
-
Dongsheng Xu [1] ; Manxia Wang [1]
-
[1] Department of Neurology, the Second Hospital of Lanzhou University, Lanzhou, Gansu, China
-
- Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 50, Nº. 6, 2022, págs. 76-83
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Objective: The aim of this study is to summarize studies on statins used to treat multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE) and its underlying mechanisms.
Methods: We searched some representing databases. Some studies were included if the effects of statins were tested on MS and EAE. The methodological quality was evaluated by the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies checklist.
Results: Studies have confirmed that statins have immunomodulatory, neuroprotective and anti-inflammatory effects, and can be used in combination with immunomodulators of different mechanisms to treat MS and EAE. Statins have been shown to improve the following symptoms MS, reduce the number of attacks and the number of lesions, through immunomodulatory, neuroprotective and anti-inflammatory effects, and has a good safety profile.
Conclusions: In short, statins represent an attractive new measure for treating MS. Some studies indicate that in addition to immunomodulatory effects, statins may have neuroprotective and neuro-repairing effects. The combination of statins with other immunosuppressive drugs has also produced encouraging results. This can be broadly prospects prospected to treat MS and EAE. It is hoped that in the near future, a combination of statins with less adverse reactions and high efficacy combined with other immunomodulators will bring exact results to patients with MS.
